GB929406A - A process for the production of encapsulated material - Google Patents

A process for the production of encapsulated material

Info

Publication number
GB929406A
GB929406A GB3916259A GB3916259A GB929406A GB 929406 A GB929406 A GB 929406A GB 3916259 A GB3916259 A GB 3916259A GB 3916259 A GB3916259 A GB 3916259A GB 929406 A GB929406 A GB 929406A
Authority
GB
United Kingdom
Prior art keywords
gelatine
treatment
preparations
membranes
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3916259A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB929406A publication Critical patent/GB929406A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
    • A01N25/28—Microcapsules or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Colloid Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

The walls of microcapsules comprised of at least one gelable hydrophilic colloid which contains amino groups and peptide linkages and produced by a coacervation process (see Group VI) are rendered opaque and their impermeability to fluids increased by successive treatment with (a) at least one watersoluble and ionizable ferric salt and, (b) an aqueous solution of one or more of tannic acid, gallic acid and di-gallic acid. Specified colloids of the above type are gelatin, fibrinogen, polylysine and polyrnithine. Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.ALSO:Membranes comprising at least one gelable hydrophilic colloid which contains amino groups and peptide linkages (e.g. proteins and polyamines) and produced by coacervation techniques are treated successively with: (1) at least one water-soluble and ionizable ferric salt and (2) an aqueous solution of one or more of tannic acid, gallic acid and digallic acid. The membranes may encapsulate solids, oils, oil-in-hydrophilic liquid and hydrophilic liquid-in-oil emulsions which may contain "active" ingredients which render the preparations of use as fertilizers, plant growth hormone preparations, bactericides, pesticides, vitamin preparations, pharmaceuticals and food-additives. In particular, the treatment renders the membranes opaque and therefore increases the stability of encapsulated preparations comprising photosensitive materials, e.g. reserpine, hyoscyamine, potassium iodide, silver salts and phenyl mercuric acetate. Specified colloids are gelatine, fibrinogen, polylysine and polyornithine. The coacervate must be gelled (e.g. by cooling) prior to the treatment with the ferric salt and may be present in the "spent" coacervating medium during the first or both steps of the treatment which preferably takes place at a pH of below 7. Specific examples refer to the treatment of: (a) aqueous potassium iodide-in-corn oil emulsion encapsulated in gelatine; (b) an ethanolic dispersion of silverbromide-in-silicone oil emulsion in gelatine; (c) aqueous epinephrine bitartrate-in-mineral oil emulsion in a complex coacervate of gelatine and styrene-maleic anhydride copolymer; (d) glyceryl monostearate coated yellow mercuric oxide in gelatine. Specifications 751,600, 911,483, 929,401, 929,402, 929,403, 929,408 and 929,409 are referred to.
GB3916259A 1958-12-22 1959-11-18 A process for the production of encapsulated material Expired GB929406A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78193058A 1958-12-22 1958-12-22

Publications (1)

Publication Number Publication Date
GB929406A true GB929406A (en) 1963-06-19

Family

ID=25124414

Family Applications (2)

Application Number Title Priority Date Filing Date
GB3916159A Expired GB929405A (en) 1958-12-22 1959-11-18 Processes for the encapsulation of particles
GB3916259A Expired GB929406A (en) 1958-12-22 1959-11-18 A process for the production of encapsulated material

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB3916159A Expired GB929405A (en) 1958-12-22 1959-11-18 Processes for the encapsulation of particles

Country Status (3)

Country Link
CH (1) CH396845A (en)
DE (1) DE1141263B (en)
GB (2) GB929405A (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808408A (en) * 1983-05-11 1989-02-28 Bend Research, Inc. Microcapsules prepared by coacervation
WO2001026627A1 (en) * 1999-10-14 2001-04-19 1170535 Ontario Inc. Liposome encapsulated silver salt compositions
WO2013123492A2 (en) 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Glucose-responsive microgels for closed loop insulin delivery
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
WO2015106106A1 (en) 2014-01-10 2015-07-16 Chamber Works, Llc A personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof
WO2015138951A1 (en) 2014-03-14 2015-09-17 Chamber Works, Llc Articles of jewelry containing a personalizing additive such as dna and methods of making
WO2016100380A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017041053A1 (en) 2015-09-04 2017-03-09 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
WO2017151879A1 (en) 2016-03-02 2017-09-08 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018053010A1 (en) 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
WO2020028907A1 (en) 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
US10722468B2 (en) 2014-08-14 2020-07-28 Brown University Compositions for stabilizing and delivering proteins
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2021258042A1 (en) 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance
WO2022115474A1 (en) 2020-11-27 2022-06-02 General Nanotherapeutics Llc Methods and composition for treatment of immune-mediated diseases
EP4053117A1 (en) 2015-08-26 2022-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965033A (en) * 1970-07-27 1976-06-22 Fuji Photo Film Co., Ltd. Process for the production of oil-containing microcapsules
CA1044134A (en) * 1975-04-09 1978-12-12 Minnesota Mining And Manufacturing Company Microcapsule insecticide composition
FR2464093A1 (en) * 1979-08-30 1981-03-06 Roussel Uclaf PROCESS FOR THE PREPARATION OF SUSPENSIONS OR STABLE POWDERS OF STABLE MICROCAPSULES WITH VARIABLE POROSITY AND THE PRODUCTS OBTAINED THEREBY
DE3016170A1 (en) 1980-04-26 1981-10-29 Bayer Ag, 5090 Leverkusen MICROCAPSULES WITH A DEFINED OPENING TEMPERATURE, METHOD FOR THE PRODUCTION AND USE THEREOF
FR2857592B1 (en) * 2003-07-18 2006-02-24 Sod Conseils Rech Applic NEW PROCESS FOR THE PREPARATION OF MICROPARTICLES
JP5036533B2 (en) 2004-04-23 2012-09-26 アムジエン・インコーポレーテツド Sustained release formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800457A (en) * 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808408A (en) * 1983-05-11 1989-02-28 Bend Research, Inc. Microcapsules prepared by coacervation
WO2001026627A1 (en) * 1999-10-14 2001-04-19 1170535 Ontario Inc. Liposome encapsulated silver salt compositions
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2013123492A2 (en) 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Glucose-responsive microgels for closed loop insulin delivery
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
WO2015106106A1 (en) 2014-01-10 2015-07-16 Chamber Works, Llc A personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof
US9539186B2 (en) 2014-01-10 2017-01-10 Chamber Works, Llc Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof
US9539187B2 (en) 2014-01-10 2017-01-10 Chamber Works, Llc Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof
US9610229B2 (en) 2014-01-10 2017-04-04 Chamber Works, Llc Personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof
WO2015138951A1 (en) 2014-03-14 2015-09-17 Chamber Works, Llc Articles of jewelry containing a personalizing additive such as dna and methods of making
US11504329B2 (en) 2014-08-14 2022-11-22 Brown University Compositions for stabilizing and delivering proteins
US10722468B2 (en) 2014-08-14 2020-07-28 Brown University Compositions for stabilizing and delivering proteins
WO2016100392A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
US10525034B2 (en) 2014-12-15 2020-01-07 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
WO2016100380A1 (en) 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
US11013719B2 (en) 2014-12-15 2021-05-25 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
EP4053117A1 (en) 2015-08-26 2022-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
WO2017041053A1 (en) 2015-09-04 2017-03-09 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
US11564890B2 (en) 2015-11-12 2023-01-31 Graybug Vision, Inc. Aggregating microparticles for medical therapy
US11331276B2 (en) 2015-11-12 2022-05-17 Graybug Vision, Inc. Aggregating microparticles for medical therapy
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017151879A1 (en) 2016-03-02 2017-09-08 The Johns Hopkins University Compositions for sustained release of anti-glaucoma agents to control intraocular pressure
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018053010A1 (en) 2016-09-13 2018-03-22 North Carolina State University Platelet compositions and methods for the delivery of therapeutic agents
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2020028907A1 (en) 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
WO2021258042A1 (en) 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance
WO2022115474A1 (en) 2020-11-27 2022-06-02 General Nanotherapeutics Llc Methods and composition for treatment of immune-mediated diseases

Also Published As

Publication number Publication date
GB929405A (en) 1963-06-19
DE1141263B (en) 1962-12-20
CH396845A (en) 1965-08-15

Similar Documents

Publication Publication Date Title
GB929406A (en) A process for the production of encapsulated material
GB930422A (en) Process of the encapsulation of particulate material
DE69430491D1 (en) METHOD FOR ENCLOSURE NSAIDS
GB1145133A (en) Process for treating polymeric material walls of minute capsules
GB929401A (en) Encapsulated emulsions and processes for their preparation
GB902061A (en) Minute colour-forming capsules
ATE36652T1 (en) PROCESS FOR MANUFACTURE OF MICROCAPSULES FOR INTRAVERSAL ADMINISTRATION.
ES416960A1 (en) Process for hardening microcapsules containing hydrophobic oil droplets
JPS56161833A (en) Preparation of microcapsule in liquid vehicle
KR850000239A (en) Preparation and Encapsulation Method of Particles
Adams et al. Pectinase in the saliva of Myzus persicae (Sulz.)(Homoptera: Aphididae)
GB1129430A (en) Process for manufacturing minute capsules
JPS62230714A (en) Enteric capsule
EP0453316B1 (en) Process for preparation of microcapsules
DE2016484A1 (en) Method of handling small capsules
ES341431A1 (en) Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material
KR900700082A (en) Gelcore
AU5256096A (en) Microencapsulation process
GB1277176A (en) Minute capsules
IE45648B1 (en) Improvements in or relating to biologically active gels
GB929403A (en) Encapsulated emulsions and processes for their preparation
GB1034437A (en) Preparation of microcapsules
ATE34407T1 (en) ENCAPSULATED CELLS, PROCESS FOR THEIR PRODUCTION AND THEIR USE.
GB929404A (en) Processes for the encapsulation of particulate material
KR100322348B1 (en) How to encapsulate substances in raw capsules